Topic

FDA approval

Clascoterone for acne: topical antiandrogen evidence

Clascoterone is an FDA-approved topical androgen receptor inhibitor for acne. See the phase 3 results, limits, adverse effects, and unanswered comparisons.

Aug 1, 2026 · 5 min · Medically reviewed

MedicalDermatologyNews

Medical

Delgocitinib for chronic hand eczema: trial evidence

Delgocitinib cream is FDA approved for some adults with chronic hand eczema. Review the phase 3 results, label limits, safety warnings, and evidence gaps.

Aug 1, 2026 · 5 min · Medically reviewed

MedicalDermatologyNews

Medical

Ruxolitinib cream for vitiligo: evidence and limits

Ruxolitinib cream can improve facial repigmentation in some people with nonsegmental vitiligo. Review the FDA label, trial outcomes, timeline, and risks.

Aug 1, 2026 · 5 min · Medically reviewed